-
1
-
-
0030956673
-
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
-
DOI 10.1056/NEJM199704033361401
-
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-9. (Pubitemid 27152782)
-
(1997)
New England Journal of Medicine
, vol.336
, Issue.14
, pp. 973-979
-
-
Ridker, P.M.1
Cushman, M.2
Stampfer, M.J.3
Tracy, R.P.4
Hennekens, C.H.5
-
2
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
JUPITER Study Group
-
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-207.
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
Genest, J.4
Gotto Jr., A.M.5
Kastelein, J.J.6
Koenig, W.7
Libby, P.8
Lorenzatti, A.J.9
MacFadyen, J.G.10
Nordestgaard, B.G.11
Shepherd, J.12
Willerson, J.T.13
Glynn, R.J.14
-
3
-
-
63649095045
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
-
JUPITER Trial Study Group
-
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-82.
-
(2009)
Lancet
, vol.373
, pp. 1175-1182
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
Genest, J.4
Gotto Jr., A.M.5
Kastelein, J.J.6
Koenig, W.7
Libby, P.8
Lorenzatti, A.J.9
Macfadyen, J.G.10
Nordestgaard, B.G.11
Shepherd, J.12
Willerson, J.T.13
Glynn, R.J.14
-
4
-
-
34447550510
-
Poor prognosis of heart transplant patients with end-stage renal failure
-
DOI 10.1093/ndt/gfl811
-
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-61. (Pubitemid 47072227)
-
(2007)
Nephrology Dialysis Transplantation
, vol.22
, Issue.5
, pp. 1383-1389
-
-
Villar, E.1
Boissonnat, P.2
Sebbag, L.3
Hendawy, A.4
Cahen, R.5
Trolliet, P.6
Labeeuw, M.7
Ecochard, R.8
Pouteil-Noble, C.9
-
5
-
-
53049095795
-
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial
-
Gissi-HF Investigators
-
Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-9.
-
(2008)
Lancet
, vol.372
, pp. 1231-1239
-
-
Tavazzi, L.1
Maggioni, A.P.2
Marchioli, R.3
Barlera, S.4
Franzosi, M.G.5
Latini, R.6
Lucci, D.7
Nicolosi, G.L.8
Porcu, M.9
Tognoni, G.10
-
6
-
-
70350512957
-
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
-
CORONA Study Group
-
Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Study Group: Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009, 54:1850-9.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 1850-1859
-
-
Cleland, J.G.1
McMurray, J.J.2
Kjekshus, J.3
Cornel, J.H.4
Dunselman, P.5
Fonseca, C.6
Hjalmarson, A.7
Korewicki, J.8
Lindberg, M.9
Ranjith, N.10
Van Veldhuisen, D.J.11
Waagstein, F.12
Wedel, H.13
Wikstrand, J.14
-
7
-
-
70349493143
-
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysis
-
CORONA Study Group
-
McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-96.
-
(2009)
Circulation
, vol.120
, pp. 2188-2196
-
-
McMurray, J.J.1
Kjekshus, J.2
Gullestad, L.3
Dunselman, P.4
Hjalmarson, A.5
Wedel, H.6
Lindberg, M.7
Waagstein, F.8
Grande, P.9
Hradec, J.10
Kamenský, G.11
Korewicki, J.12
Kuusi, T.13
Mach, F.14
Ranjith, N.15
Wikstrand, J.16
-
8
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
AURORA Study Group
-
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-407.
-
(2009)
N Engl J Med
, vol.360
, pp. 1395-1407
-
-
Fellström, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
Holdaas, H.4
Bannister, K.5
Beutler, J.6
Chae, D.W.7
Chevaile, A.8
Cobbe, S.M.9
Grönhagen-Riska, C.10
De Lima, J.J.11
Lins, R.12
Mayer, G.13
McMahon, A.W.14
Parving, H.H.15
Remuzzi, G.16
Samuelsson, O.17
Sonkodi, S.18
Sci, D.19
Süleymanlar, G.20
Tsakiris, D.21
Tesar, V.22
Todorov, V.23
Wiecek, A.24
Wüthrich, R.P.25
Gottlow, M.26
Johnsson, E.27
Zannad, F.28
more..
-
9
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-48.
-
(2005)
N Engl J Med
, vol.353
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
März, W.3
Olschewski, M.4
Mann, J.F.5
Ruf, G.6
Ritz, E.7
-
10
-
-
52649120889
-
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
-
SEAS Investigators
-
Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-56.
-
(2008)
N Engl J Med
, vol.359
, pp. 1343-1356
-
-
Rossebø, A.B.1
Pedersen, T.R.2
Boman, K.3
Brudi, P.4
Chambers, J.B.5
Egstrup, K.6
Gerdts, E.7
Gohlke-Bärwolf, C.8
Holme, I.9
Kesäniemi, Y.A.10
Malbecq, W.11
Nienaber, C.A.12
Ray, S.13
Skjaerpe, T.14
Wachtell, K.15
Willenheimer, R.16
-
11
-
-
68049114763
-
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in Endpoints through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease
-
Steering Committees of IDEAL and TNT Trials
-
Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR; Steering Committees of IDEAL and TNT Trials: Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in Endpoints through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009, 104:459-63.
-
(2009)
Am J Cardiol
, vol.104
, pp. 459-463
-
-
Faergeman, O.1
Holme, I.2
Fayyad, R.3
Bhatia, S.4
Grundy, S.M.5
Kastelein, J.J.6
LaRosa, J.C.7
Larsen, M.L.8
Lindahl, C.9
Olsson, A.G.10
Tikkanen, M.J.11
Waters, D.D.12
Pedersen, T.R.13
-
12
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
ACCORD Study Group
-
ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-74.
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
Crouse III, J.R.4
Leiter, L.A.5
Linz, P.6
Friedewald, W.T.7
Buse, J.B.8
Gerstein, H.C.9
Probstfield, J.10
Grimm, R.H.11
Ismail-Beigi, F.12
Bigger, J.T.13
Goff Jr., D.C.14
Cushman, W.C.15
Simons-Morton, D.G.16
Byington, R.P.17
-
13
-
-
50949102416
-
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
-
IMPROVE-IT Investigators
-
Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators: Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826-32.
-
(2008)
Am Heart J
, vol.156
, pp. 826-832
-
-
Cannon, C.P.1
Giugliano, R.P.2
Blazing, M.A.3
Harrington, R.A.4
Peterson, J.L.5
Sisk, C.M.6
Strony, J.7
Musliner, T.A.8
McCabe, C.H.9
Veltri, E.10
Braunwald, E.11
Califf, R.M.12
-
14
-
-
33646258753
-
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans
-
Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, Waters MG: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006, 103:6682-7.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 6682-6687
-
-
Cheng, K.1
Wu, T.J.2
Wu, K.K.3
Sturino, C.4
Metters, K.5
Gottesdiener, K.6
Wright, S.D.7
Wang, Z.8
O'Neill, G.9
Lai, E.10
Waters, M.G.11
-
15
-
-
53149118030
-
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
-
Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF: Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Intl J Clin Prac 2008, 62:1959-70.
-
(2008)
Intl J Clin Prac
, vol.62
, pp. 1959-1970
-
-
Maccubbin, D.1
Bays, H.E.2
Olsson, A.G.3
Elinoff, V.4
Elis, A.5
Mitchel, Y.6
Sirah, W.7
Betteridge, A.8
Reyes, R.9
Yu, Q.10
Kuznetsova, O.11
Sisk, C.M.12
Pasternak, R.C.13
Paolini, J.F.14
|